Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia

Soyoung Jeon[1,2], Adam J. de Smith[1], Shaobo Li[1,2], Minhui Chen[1], Ivo S. Muskens[1], Libby M. Morimoto[3], Andrew T. DeWan[4,5], Nicholas Mancuso[1,6,7], Catherine Metayer[3], Xiaomei Ma[5,8], Joseph L. Wiemels[1], Charleston W.K. Chiang[1,6]

Affiliations:

1. Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA
2. Cancer Biology and Genomics Graduate Program, Program in Biological and Biomedical Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA
3. Division of Epidemiology & Biostatistics, School of Public Health, University of California, Berkeley, CA
4. Center for Perinatal, Pediatric and Environmental Epidemiology, Yale School of Public Health, New Haven, CT
5. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT
6. Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA
7. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
8. Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT

Correspondence: J.L.W. (wiemels@usc.edu), C.W.K.C. (charleston.chiang@med.usc.edu)

24 ABSTRACT

The incidence patterns of childhood acute lymphoblastic leukemia (ALL) differ across ethnic
groups but have been studied mostly in populations of predominantly European ancestries. Risk
variants identified from previous genome-wide association studies (GWAS) do not fully explain
heritable risk. In an effort to address these limitations, we performed a meta-analysis of ALL in
76,317 participants across four ethnic groups, including 17,814 non-European individuals and
3,482 total cases. We generally replicated previously identified loci associated with ALL (15 out
of 16 loci replicated after Bonferroni corrections). We further identified five novel associations
at genome-wide significance, including three novel loci and two secondary associations at
previously known loci (17q12 and near *CEBPE*). The three putatively novel loci (rs9376090 near
MYB/HBS1L on chr6q23.3, rs10998283 near *TET1* on chr10q21.3, and rs9415680 near
JMJD1C/NRBF2 on chr10q21.3) were previously shown to be associated with multiple blood
cell traits and other hematopoietic cancers. When trans-ethnic information is used, polygenic risk
scores constructed from GWAS loci in our trans-ethnic meta-analysis showed similar efficacy in
independent Latino (LAT) and non-Latino white (NLW) ALL cohorts (AUC ~ 0.67-0.68) and
could partly explain the increased risk of ALL in LAT compared to NLW. Cross-population
analysis also showed high but significantly less than 100% genetic correlation between LAT and
NLW, suggesting potential differences in the underlying genetic architecture between ethnic
groups. In summary, our findings enhance the understanding of genetic contribution to ALL risk
across diverse populations and highlight the importance to include multiple ethnic groups in
GWAS.

INTRODUCTION

Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer worldwide, with substantial racial and ethnic differences in incidence and treatment outcome[1,2]. Previous genome-wide association studies (GWAS) have confirmed the genetic basis of ALL susceptibility by identifying a number of risk loci that confer risk of childhood ALL including in *ARID5B, IKZF1, CEBPE, CDKN2A, PIP4K2A, LHPP* and *ELK3*, among others[3–8]. However, these studies were generally composed of participants with a predominantly European ancestry, and efforts to replicate these findings in other ethnic groups have been limited, leading to a gap in our understanding of the genetic architecture of ALL in non-European populations. For example, among major ethnic groups in the United States, Latino children have the highest risk of ALL, with an incidence rate ~15-40% higher than in non-Latino whites[9–11], and an increased chance of relapse and poorer overall survival[12,13]. Yet, individuals outside of the non-Latino white group (Latinos, African Americans and Asians) are generally underrepresented in GWAS, with the exception of recent efforts for childhood ALL in Latinos[14–16]. While environmental or social factors likely underlie some if not the majority of the differences in risk between ethnic groups, there may also be a difference in the genetic risk architecture of the disease across ethnic groups.

The previously identified risk loci for ALL are generally common (except for a low frequency missense variant in *CDKN2A*[17]) in European ancestry populations. The heritability of ALL was estimated to be 21% in the European ancestry population, but the known risk loci together account for a relatively small portion of the total variance in genetic risk of ALL[18]. This suggests that additional susceptibility alleles may yet to be discovered in larger genetic studies of ALL. Moreover, polygenic risk scores (PRS) hold great promise for preventive risk assessment and stratification in a population, but are known to be poorly transferred to non-European populations[19]. It has been shown that PRS derived from multi-ethnic GWAS summary statistics would be more transferrable between populations, since multi-ethnic designs are more effective to identify alleles with shared effects across population without explicit fine-mapping[20,21].

Given this context, we performed a trans-ethnic GWAS of childhood ALL in a discovery panel consisting of 76,317 individuals from a multi-ethnic cohort derived from the California birth population and Kaiser's Cohort for Genetic Epidemiology Research on Aging. Our cohort consisted of 3,482 cases and 72,835 controls for an effective sample size of 13,292(Methods). We note the complexity of discussing race, ethnicity and ancestry in a genetic study. As a convention, we used the following term and abbreviations to refer to each ethnic group in our study: African American (AFR), East Asian (EAS), Latino American (LAT), and non-Latino white (NLW). These population labels are largely based on self-reported ethnic identity and we confirmed that they largely correlate with genetic ancestry as defined by the reference populations in 1000 Genomes[22] (Methods). To our knowledge, this is the largest trans-ethnic GWAS for ALL to date. We identified three novel ALL risk loci and tested the novel findings from our discovery panel in two independent cohorts with cases from the California Childhood Leukemia Study and the Children's Oncology Group cohort. We further compared the efficacy of PRS to stratify individuals based on their risk of ALL in the two largest subgroups of our data, LAT and NLW, and contrasted the genetic architecture of ALL between them.

SUBJECTS AND METHODS

Study Subjects in Discovery Cohort

The California Childhood Cancer Record Linkage Project (CCRLP) includes all children born in California during 1982-2009 and diagnosed with ALL at the age of 0-14 years per California Cancer Registry records. Children who were born in California during the same period and not reported to California Cancer Registry as having any childhood cancer were considered potential controls. For each case, one control subject was randomly selected from a pool of potential controls and matched to case on year and month of birth, sex (56% male, 44% female), and ethnicity. A detailed information on sample preparation and genotyping has been previously described.[4] Furthermore, because ALL is a rare childhood cancer, for the purpose of a genetic study we incorporated additional controls using adult individuals from the Kaiser Resource for Genetic Epidemiology Research on Aging Cohort (GERA). The GERA cohort was chosen because a very similar genotyping platform had been used: Affymetrix Axiom World arrays. The GERA genotype information was downloaded from dbGaP (Study Accession: phs000788.v1.p2).

Data Processing and Quality Control

The quality control (QC) on single nucleotide polymorphism (SNP) array genotypes and samples were carried out in each population and dataset in parallel, performed in two stages: pre-imputation and post-imputation. In pre-imputation QC, the sex chromosomes were excluded, and SNPs were filtered out on the basis of call rate (<98%), minor allele frequency (MAF<0.01), genome-wide relatedness (PI_HAT>0.02), genome heterozygosity rate (mean heterozygosity± 6Std), and deviation from Hardy-Weinberg equilibrium in controls ($P<10^{-5}$). Samples with call rate < 95% were also removed. In general, individuals were included in each of the four ethnic groups based on their self-reported ethnicity. We did not attempt to reassign individuals to different ethnic groups based on estimated genetic ancestry. We did perform principal components analysis for each population including our study subjects along with 1000 Genomes Project reference data[22] to identify extreme outlier individuals that clustered apart from other individuals in their self-reported race/ethnicity groups: this identified a small subset of individuals (29 cases and 51 controls from CCRLP, 31 individuals from GERA) among self-reported Asians (total n=722) that clustered with South Asian reference individuals, as well as 5 self-reported African American individuals out of n=3572 from the GERA cohort that clustered with East Asian reference individuals. These appear to result from a lack of finer-scale ethnic labels for self-report, or a mis-labeling of individual records, and these individuals were dropped from our analysis.

To control for potential batch effect and systematic bias between array types, we performed two separate GWASs. First, stratified by ethnicity and restricted to post-QC SNPs in both CCRLP and GERA, we compared CCRLP controls and GERA individuals. Second, using the GERA NLW cohort we compared individuals that were genotyped on the Axiom type "A" to those genotyped on the type "O" reagent kit (NLW was the only cohort in GERA that was genotyped using both reagent kits). Twenty principal components (PCs) were included as covariates of the logistic regression. In both comparisons we observed inflation of the test statistics suggesting a subset of SNPs exhibited evidence of batch effect, thus we removed variants with P < 0.01 in any of the comparisons from all populations.

135
We then performed genome-wide imputation with the overlapping set of remaining SNPs (N =
431,543 in AFR, 259,468 in EAS, 547,575 in LAT and 362,977 in NLW) in each dataset using
Haplotype Reference Consortium (HRC v r1.1 2016) as a reference in the Michigan Imputation
Server[23]. The different number of SNPs passing QC and used in imputation reflects the fact that
each ethnic group in CCRLP was genotyped using Affymetrix World arrays optimized for the
Latino population (i.e., Axiom LAT array). In post-imputation QC, we filtered variants in each
ethnic group by imputation quality ($R^2 < 0.3$), MAF (< 0.01), and allele frequency difference
between non-Finnish Europeans in the Genome Aggregation Database (gnomAD)[24] and CCRLP
NLW controls (> 0.1). We next performed another GWAS between CCRLP controls and GERA
individuals, and removed variants with $P < 1x10^{-5}$. In principal components analysis using
imputed data, we identified and removed 31 individuals in GERA LAT that were extreme
outliers after imputation in PCs 1 to 20. Stratified by ethnicity, the CCRLP and GERA datasets
were then merged to perform GWAS of ALL. In total, 124, 318, 1878, 1162 cases and 2067,
5017, 8410, 57341 controls, in AFR, EAS, LAT and NLW, respectively were used in GWAS for
ALL. An effective population was calculated using this equation:
151

152
$$N_{eff} = \frac{4}{\frac{1}{N_{cases}} + \frac{1}{N_{controls}}}$$

153
154 where N_{eff} is the effective sample size, N_{cases} is the number of cases, and $N_{controls}$ is the number of
155 control subjects. A total of 7,628,894 SNPs that remained in at least three ethnic groups were
156 tested in our GWAS discovery analysis.

Association Testing in Discovery Cohort

In each ethnic strata, we used SNPTEST[26] (v2.5.2) to test the association between imputed
genotype dosage at each SNP and case-control status in logistic regression, after adjusting for the
top 20 PCs. The result from the four ethnic-stratified analyses were combined via the fixed-effect
meta-analysis with variance weighting using METAL[25]. Only variants passing QC in at least
three of the four ethnic groups were meta-analyzed. A genome-wide threshold of 5×10^{-8} was
used for significance. We also tested to ensure sex is not correlated with the genotype dosage of
SNPs with $P < 5 \times 10^{-7}$ in our meta-analysis, thus our results are not explained by sex as a
confounder.

For replication of previously identified ALL risk loci, we focused on the variants within 1Mb of
the previously reported susceptibility variants[3–8,17,27,28]. We report the association results of the
published lead SNP as well as the top SNP at each locus from our meta-analysis. For replication
of the known loci, a significance of 0.00312 (=0.05/16) was used.

To identify secondary signals at each of the three putatively novel and 16 previously known risk
loci, we performed multivariate conditional analysis adjusting for the lead SNP and 20 PCs. A
second round of conditional analyses conditioning on the top and the second top SNP resulted in
no additional SNPs reaching genome-wide significance at any of the loci examined. A genome-
wide threshold of 5×10^{-8} was used for significance.

Association Testing in Replication Cohorts

We included two independent ALL case-control replication studies: (1) individuals of predominantly European ancestry from the Children's Oncology Group (COG, [dbGAP accession number phs000638.v1.p1]) cohort as cases and from Wellcome Trust Case–Control Consortium[29] (WTCCC) as controls, genotyped on either the Affymetrix Human SNP Array 6.0 (WTCCC, COG trials AALL0232 and P9904/9905) or the Affymetrix GeneChip Human Mapping 500K Array (COG P9906 and St. Jude Total Therapy XIIIB/XV[18]); and (2) individuals of European and Latino ancestry from the California Childhood Leukemia Study (CCLS), a non-overlapping California case-control study (1995-2008).[30] The quality control procedures and imputation were performed in accordance with the discovery cohort. For COG and WTCCC, because self-identified ethnicity was not available to us, we performed global ancestry estimations using ADMIXTURE and the 1000 Genomes populations as reference and removed individuals with < 90% estimated European ancestry from the analysis. This resulted in 1504 cases and 2931 controls from COG/WTCCC, and in the CCLS, 426 NLW cases, 278 NLW controls, 758 LAT cases and 549 LAT controls for our replication analysis. In each dataset, we tested the imputed SNP dosages in the three putatively novel loci with $P < 5 \times 10^{-7}$ (number of SNPs=141) in logistic regression with top 20 PCs as covariates using PLINK[31] (v2.3 alpha).

Polygenic Risk Score Analysis

Polygenic risk scores (PRS) for ALL were constructed for each individual in CCLS LAT, NLW, and COG/WTCCC by summing the number of risk alleles, each weighted by its effect size from our discovery GWAS meta-analysis. PRS were constructed in two different ways: (1) a PRS with lead SNPs in the 16 known loci (N = 18 SNPs, including variants from the two secondary signals in *IKZF1* and *CDKN2A/B* that were previously reported; for which we used the corresponding effect sizes from conditional analysis), and (2) a PRS including the novel hits (A total of 19 loci and 23 SNPs, including the additional 3 novel loci and 2 novel conditional associations). The lead SNPs in known loci included in both models were from this study. PRS was computed using PLINK (v2.0) where the effect size of each risk allele was multiplied by the genotype dosage and summed to generate a score for each sample. Associations between PRS and case-control status for ALL were tested in each group adjusting for 20 principal components using R. To evaluate the predictive power of PRS, Area Under the receiver operating characteristic Curve (AUC) were calculated using pROC package[32] in R.

Heritability Estimates

We estimated heritability ascribable to all post-QC imputed SNPs with MAF ≥ 0.05 in our GWAS data using the genome-wide complex trait analysis software (GCTA)[33]. We followed the GCTA-LDMS approach to estimate heritability from imputed data[34], which recommended stratifying SNPs into bins based on their LD scores and/or minor allele frequency. Using GCTA, we computed the genetic relationship matrix (GRM) of pairs of samples using SNPs in each bin, and used the multiple GRMs as input to obtain a restricted maximum likelihood (REML) estimate of heritability. All individuals in discovery analysis were used for LAT (n=10,288). For computational efficiency and for maintaining a close balance in sample size to the LAT data, we randomly sampled 10,000 NLW GERA controls to be included with all of CCRLP NLW cases

and controls (total N = 12,391). We used a prevalence of 4.41×10^{-4} and 4.09×10^{-4} for childhood
ALL in LAT and NLW respectively based on data from the Surveillance Research Program,
(National Cancer Institute SEER*Stat software version 8.3.8; https://seer.cancer.gov/seerstat) to
convert the estimated heritability to the liability scale. Because the NLW are expected to be
much better imputed using HRC than LAT, particularly at rare variants, our genome-wide
imputed data potentially could be used to partition the contribution of low frequency ($0.01 \leq$
MAF < 0.05) and common (MAF ≥ 0.05) variants in NLW population. In this case, we
performed GCTA-LDMS analysis in 8 strata: two MAF strata (low frequency and common) by
four quartiles of LD score strata.

To measure genetic correlation between LAT and NLW, we used SNPs with MAF ≥ 0.05 in
both populations to generate GRM using R as per Mancuso et al.[35] The individuals used in
univariate REML for each ethnicity were used for the bivariate analysis (n=22,679). We used
imputed dosage data to estimate GRM for each unique pair of ancestry groups as

$$A = \frac{1}{m} \begin{bmatrix} Z_1 \\ Z_2 \end{bmatrix} \cdot \begin{bmatrix} Z_1 \\ Z_2 \end{bmatrix}^t$$

234 where m is number of SNPs and Z_1 and Z_2 are the standardized genotype matrices for LAT and
235 NLW, respectively. We estimated genetic correlation using bivariate GREML in GCTA.

Investigation of Genetic Architecture

To quantify the extent to which latent causal variants for ALL are shared or population-specific
between LAT and NLW, we analyzed our GWAS summary data using the tool PESCA[36].
Briefly, PESCA analyzes GWAS summary data from multiple populations jointly to infer the
genome-wide proportion of causal variants that are population-specific or population-shared. For
computational efficiency, PESCA requires first defining LD blocks that are approximately
independent in both populations and assumes that a SNP in a given block is independent from all
SNPs in all other blocks. We computed pairwise LD matrix in both NLW and LAT using ~329K
directly genotyped SNPs shared in both populations. Then, following Shi et al.[36], we generated
the trans-ethnic LD matrix by using the larger r^2 value of the NLW or LAT-specific pairwise LD,
and used LDetect [37] to define LD blocks within the transethnic LD matrix. By setting mean LD
block size to 200 SNPs and using default parameters, we obtained 1,653 blocks that are
approximately independent, which is approximately similar to previous reports in East Asians
and Europeans.[36] We then followed Shi et al. to estimate the numbers of population-specific and
shared causal SNPs using PESCA[36]. We restricted our analysis to 1.3M SNPs with MAF > 0.05,
r^2 < 0.95, and with summary association statistics available in both NLW and LAT. We first
estimated the genome-wide proportion of population-specific and shared causal variants with the
heritability estimated above (0.2033 and 0.0413 in NLW and LAT, respectively) using default
parameters in PESCA, parallelizing the analysis in groups of 10 LD blocks at a time. Using the
estimated genome-wide proportions of population-specific and shared causal variants as prior
probabilities, we then estimated the posterior probability of each SNP to be causal in a single
population (population-specific) or both populations (shared), and inferred the posterior expected
numbers of population-specific/shared causal SNPs in each LD block by summing the per-SNP
posterior probabilities of being causal in a single or both populations. Critically, while PESCA is

an analysis based on summary statistics and not designed for admixed populations, it can be
applied to admixed population such as LAT if in-sample LD is used.[36]

Familial risk per variant

The percentage of familial relative risk (FRR) explained by each genetic variant was calculated
as per Schumacher et al[38]5/7/2021 10:41:00 PM . The familial relative risk due to locus k (λ_k) is
given by

267
$$\lambda_k = \frac{p_k r_k^2 + q_k}{(p_k r_k + q_k)^2}$$

where p_k is the frequency of the risk allele for locus k in each population, $q_k = 1 - p_k$, and r_k is
the estimated per-allele odds ratio from meta-analysis. The percentage of familial relative risk is
calculated as $\sum_k \log \lambda_k / \log \lambda_0$ where λ_0 is the observed familial risk to first-degree relatives of
ALL cases, assumed to be 3.2 as per Kharazmi et al.

RESULTS

Trans-ethnic Genetic Associations with ALL

We performed a trans-ethnic meta-analysis GWAS for childhood ALL. After quality control
filtering, our dataset consisted of 3,482 cases and 72,835 controls (124 cases/ 2,067 controls in
AFR, 318 cases/5,017 controls in EAS, 1,878 cases/ 8,410 controls in LAT, 1,162 cases/ 57,341
controls in NLW; see Materials and Methods) in total. Compared to the previous trans-ethnic
analysis, we included additional controls for NLW, added data from EAS population. In
addition, we also tested the association at a total of 7,628,894 SNPs after imputation using the
Haplotype Reference Consortium reference panel (HRC v r1.1.2016). We aggregated the
summary statistics across the four ethnic groups in a fixed-effect meta-analysis. The genomic
control inflation factor was 1.023 (1.022 after removing 16 previously known ALL-associated
loci, Table 1), suggesting our meta-analysis was not impacted by uncontrolled confounding due
to population stratification (Figure 1). Twelve loci reached genome-wide significance (i.e, P <
5.0 X 10[-8]).

We first examined the evidence of association at 16 previously published risk loci for ALL[3–]
[8,16,18,27,28] . Across the 16 loci, all replicated at the nominal level (P < 0.05) or have a SNP nearby
with strong association (Table 1), including nine that reached genome-wide significance. Note
that out of the 16 loci, three(8q24.21, *IKZF3*, and *BMI1*) were initially identified and five
(*IKZF1, PIP4K2A, ARID5B, CDKN2A, CEBPE*) were previously shown to be replicated using a
smaller but largely overlapping subset of this dataset[4,28]. For these loci, our findings here would
not necessarily constitute an independent replication. In some cases, the published SNP is not the
SNP with the most significant association in our dataset, though usually our top SNP in the locus
is in strong LD with the reported SNP (Table 1). Interestingly, at the *C5orf56* locus on 5q31
previously identified in an independent cohort of predominantly European ancestry, the reported
variant (rs886285) was not nominally significant (P = 0.63) in our dataset, presumably due to
this SNP being associated with a particular subtype of ALL (HD-ALL)[18]. Another SNP in the
same locus approximately 20kb away (rs11741255) but in low LD (r2 = 0.35 in NLW, 0.19 in

LAT) was significantly associated with ALL in our data (P = 1.69x10^{-4}) but may reflect a chance
association. At another locus (*TLE1* on 5q21), neither the published variant nor our top variant in
the locus would be considered significantly associated after correcting for multiple testing of 16
SNPs in this analysis (minimum P = 1.06x10^{-2} for rs62579826), possibly due to heterogeneity
driven by EAS in which both the published variant and our top variant are monomorphic[24].
Therefore, further characterization at these two loci is needed to determine whether there is a
reproducible association signal to ALL and if so, which are the more likely causal variants.
308
More importantly, we discovered three putatively novel susceptibility loci: one at 6q23 and two
at 10q21 (Figure 1). The strongest association signal in 6q23 is at rs9376090 (P= 8.23 X 10^{-9},
OR=1.27) in the intergenic region between *MYB* and *HBS1L* (Figure 2A). This association is
mainly driven by NLW presumably due to its large sample size (Supplementary Table S1). In
10q21, there were two independent signals that showed genome-wide significance. One locus
was identified with the lead SNP rs9415680 (P=7.27 X 10^{-8}, OR=1.20), within a broad
association peak, with apparently long-range LD with SNPs covering *NRBF2, JMJD1C*, and
parts of *REEP3* (Figure 2B). The second locus in 10q21 was identified 5Mb away, with lead
SNP rs10998283 (P=3.92x10^{-8}, OR=1.15) in an intronic region in *TET1* (Figure 2C). The
association signals for both loci in 10q21 were largely driven by LAT. We used the convention
of the nearest genes to refer to these loci for the remainder of the manuscript, acknowledging that
they may not be the causal genes.
321
To replicate the novel associations in independent datasets, we tested the associations of the
three novel variants and their LD proxies (with P < 5 x 10^{-7};n=141) in independent samples from
COG/WTCCC NLW, and CCLS LAT and NLW. For the *MYB/HBS1L* locus, which was driven
by NLW in the discovery cohort, we replicated the signal in COG/WTCCC cohort (rs9376090,
P_{COG} = 4.87x10^{-3}, $P_{COG+discovery\ analysis}$ = 1.23x10^{-10}; Supplementary Table S2), but did not replicate
in CCLS likely owing to the small sample size of NLW. For the *TET1* locus, in which the
original association was driven by LAT in the discovery, three of the four SNPs with P < 5x10^{-7}
in the discovery cohort nominally replicated in CCLS. The lead SNP after meta-analyzing the
discovery cohort and the replication cohort of CCLS was rs79226025 (P_{CCLS} = 3.04 x10^{-2},
$P_{CCLS+discovery}$ = 6.81 x10^{-9}; Supplementary Table S2). For the *NRBF2 / JMJD1C* locus, we did
not observe an association in the replication cohorts.
333
Novel secondary signals at known loci
We performed conditional analyses adjusting for the lead SNP at each of the known and novel
loci to test for independent secondary associations contributing to ALL risk. Using a genome-
wide significance threshold of P<5x10^{-8}, we identified a secondary signal in four out of the 16
previously known loci (Table 2, Figure 3). In all cases, the LD between the secondary hit and the
top hit in the locus are low (Table 2). The additional second associations in *CDKN2A* and *IZKF1*
loci were previously noted[18]. In *CEBPE* (rs60820638, P=5.38 x10^{-8}) and 17q12 (rs12944882,
P=7.71 x10^{-10}), these secondary signals represent novel associations. In particular, at the *CEBPE*
locus, previous reports suggest multiple correlated variants with functional evidence[39,40] . Our
analysis is consistent with the two previous variants (rs2239635 and rs2239630) being or tagging
the same underlying signal, while the secondary association we identified (rs60820638) is an
independent association (Supplementary Table S3). In the case of 17q12 the lead SNP in our

discovery GWAS is the novel association, as the conditional analysis revealed the previously
known SNP at the locus. The LD between the two associated SNPs is low ($r2 = 0.02$). None of
the loci tested showed residual association surpassing genome-wide significance threshold after
conditioning on the first or second associated variants, and none of the three putatively novel loci
showed additional association in conditional analysis.

351
352 **Polygenic Risk Score**
353
To assess the combined effect of all identified risk alleles for ALL, we constructed an ALL PRS
model in our discovery cohort, using either the 18 SNPs from 16 previously known loci or the 23
known plus novel SNPs (including the novel conditional hits) and their associated effect sizes
from the trans-ethnic meta-analysis in CCRLP/GERA. We then computed the PRS for NLW and
LAT individuals in CCLS and COG, as they are the largest ethnic groups available across CCLS,
COG/WTCCC, and our discovery cohort. The scores generated with the known risk loci were
significantly associated with case-control status in all groups ($P_{CCLS\ NLW}=2.22 \times 10^{-17}$, P_{CCLS}
$_{LAT}=4.78 \times 10^{-23}$, $P_{COG/WTCCC}=2.99 \times 10^{-62}$, Supplementary Table S4). Adding the three novel loci
identified in this study and the two novel secondary signals further strengthened the evidence of
the association in COG/WTCCC ($P = 6.93 \times 10^{-63}$) and CCLS LAT ($P = 5.75 \times 10^{-24}$), while the
evidence of association stayed about the same in CCLS NLW ($P = 2.03 \times 10^{-17}$). The predictive
accuracy as measured by AUC are similar between NLW and LAT, at around 67-68%, consistent
with the hypothesis that trans-ethnic meta-analysis will enable PRS to be more transferrable
between populations.
368
Also, we explored the distribution of PRS in CCRLP individuals (Supplementary Figure S1). We
found that while the shape of the PRS distribution is consistent with a normal distribution
(Kolmogorov-Smirnov $P = 0.918$ and 0.303 for LAT and NLW, respectively) and appears
similar between LAT and NLW (standard deviation of 0.728 and 0.735 respectively; F-Test $P =$
0.633), the scores in LAT are shifted to the right compared to the scores in NLW (mean of 5.101
and 4.641 respectively, Welch t-test $P = 1.3 \times 10^{-122}$). The observed pattern was consistent when
the scores were stratified by case-control status (mean of 5.324 and 4.881 in LAT and NLW
cases, respectively, $P=3.956 \times 10^{-58}$; mean of 4.895 and 4.414 in LAT and NLW controls,
respectively, with $P= 1.493 \times 10^{-78}$). This observation was also replicated in CCLS with mean of
5.119 in LAT and 4.607 in NLW ($P=4.596 \times 10^{-51}$). Therefore, results from our PRS analyses are
consistent with the notion that differences in allele frequency of ALL risk loci between
populations may complement other non-genetic factors for ALL risk, and partly explain the
increased ALL risk in LAT relative to NLW children and LAT.
382
383 **Genetic architecture of ALL in Latinos and non-Latino whites**
384
We estimated the relative contributions of each variant to ALL risk by computing the familial
relative risk (Supplementary Table 5). In our discovery cohort (CCRLP/GERA), the known risk
variants account for 22.9% and 21.7% familial relative risk in LAT and NLW respectively, while
the addition of the novel variants increased this estimate to 25.9% and 24.6%, respectively. In
CCLS, where effect size estimates are expected to be less biased by winner's curse, the pattern is
similar: 22.7% and 23.2% explained in LAT and NLW using known risk variants, and 24.3%

and 24.8% explained in LAT and NLW using both known and novel variants (Supplemental
Table S5).
393
We also estimated the heritability of ALL attributable to all common SNPs (MAF $\geq$ 0.05) using
the GCTA-LDMS framework.[34] We estimated the heritability to be 20.3% in NLW and 4.1% in
LAT (Supplemental Table S6A). The low estimate in LAT remained with using only the CCRLP
cohort (Supplemental Table S6C). The low estimates could be unreliable because of the admixed
nature of LAT (see Discussion). The estimated heritability in NLW is consistent with that
previous reported[18]. Because the imputation quality using HRC reference panel is expected to be
high for low frequency variants between 1-5% MAF in NLW, our dataset also provides the
opportunity to estimate the stratified contribution by allele frequency to the heritability of ALL
in NLW. When low frequency variants are included, the estimated heritability in NLW increased
to 29.8% (16.2% due to common variants, 13.5% due to low frequency variants; Supplemental
Table S6B). Furthermore, we sought to measure the genetic correlation for ALL between NLW
and LAT, using bivariate GREML analysis implemented in GCTA. The genetic correlation was
high (rG = 0.714 $\pm$ standard error 0.130) but significantly different from 1 (P = 0.014,
Supplementary Table 7), indicating the genetic architectures may be similar as expected from
correlated effect sizes (Supplementary Figure S2) but not perfectly concordant. Taken at face
value, this may suggest that there may be ethnic-specific genetic risk profiles or differential
interactions with the environment that contributes to differences in disease risk between NLW
and LAT, although it may be subject to similar concerns as the low univariate estimate due to
admixture.
413
Finally, we further characterized the genetic architecture of ALL in NLW and LAT by
estimating the number of population-specific and shared causal alleles using the program
PESCA[36]. The PESCA framework defines the set of causal variants as all variants tested to have
a non-zero effect, even if the effect is indirect and only statistical rather than biological in nature.
Using this framework, we estimated that approximately 1.71% of common SNPs have nonzero
effects in both NLW and LAT, and that 1.69% and 1.87% had population-specific nonzero
effects in NLW and LAT, respectively. By dividing the genome into 1,653 approximately
independent LD regions (Methods), the mean expected numbers of population-specific/shared
causal SNPs were 13.86 (SD 7.23) NLW-specific, 15.32 (SD 8.00) LAT-specific, and 14.02 (SD
7.32) shared by the two populations (Supplementary Figure S3).
424
425
426 **DISCUSSION**
427
In summary, we have performed the largest trans-ethnic meta-analysis GWAS of childhood ALL
to date. We incorporated data across four ethnic groups (2,191 AFR, 5,335 EAS, 10,288 LAT,
and 58,503 NLW individuals) and identified three putatively novel susceptibility loci. In
addition, conditional analyses identified novel secondary associations with ALL in two
previously reported loci. Our analysis suggests that the known and novel ALL risk alleles
together explained about 25% of the familial relative risk in both NLW and LAT populations,
and that the trans-ethnic PRS we constructed, although relatively simple and utilizing only the
genome-wide associated variants, performed similarly in both NLW and LAT in predicting ALL
(AUC ~ 67-68%).

437
While the three putatively novel risk loci were not consistently replicated, possibly due to small
sample sizes in our replication cohorts and population differences in SNP risk effects, each of the
three loci harbors genes and/or variants with reported functions in hematopoiesis and
leukemogenesis that support a potential role in ALL etiology. Among the set of significantly
associated SNPs ($P_{meta} < 5x10^{-7}$) in the three putatively novel loci, annotations from HaploReg
(version 4.1) [41] and GTEx portal[42] provided insights of the biological basis of these novel
associations. The associated variants in 6q23 are located between *HBS1L* and *MYB*, a
myeloblastosis oncogene that encodes a critical regulator protein of lymphocyte differentiation
and hematopoiesis[43] . This locus is already well known for associations with multiple blood cell
measurements, severity of major hemoglobin disorders, and β-thalassemia, with multiple
putative functional variants reported[44,45]. The *HBS1L-MYB* intergenic variants are also known to
reduce transcription factor binding, affect long-range interaction with *MYB*, and impact *MYB*
expression. The lead SNP rs9376090 is in a predicted enhancer region in K562 leukemia cells
and GM12878 lymphoblastoid cells, and is a known GWAS hit for platelet count[43] and
hemoglobin concentration[46,47]. Also, it is an eQTL for *ALDH8A1in* lymphocytes and whole
blood[42]. *ALDH8A1* encodes aldehyde dehydrogenases, a cancer stem cell marker and a regulator
self-renewal, expansion, and differentiation.
455
One of the associated loci in 10q21 has a distinct haplotype structure, with 130 highly correlated
SNPs ($r^2 > 0.8$) associated with ALL. This haplotype structure is observed in LAT and EAS, and
the associations are driven by alleles with higher frequency in LAT and EAS than NLW or AFR
(Supplementary Table S1, Supplementary Figure S4). This 400kb region is rich with genetic
variants associated with blood cell traits such as platelet count, myeloid white cell count, and
neutrophil percentage of white cells[48,49]. It is also associated with IL-10 levels[50] which was
shown to be in deficit in ALL cases[51]. The signal region is contained within the intron of
JMJD1C, a histone demethylase that a recent study has found to regulate abnormal metabolic
processes in AML[52]. Previous studies have found that it acts as a coactivator for key transcription
factors to ensure survival of AML cells[53] and self-renewal of mouse embryonic stem cells[54].
Moreover, several significantly associated variants in this region found in our study alter binding
motif of some important transcription factors such as Pax5 and TCF12(ref.[41]).
468
The second locus in 10q21 contains intronic variants in the *TET1* gene, which is well known for
its oncogenicity in several malignancies including AML[55]. A recent study showed the epigenetic
regulator *TET1* is highly expressed in T-cell ALL and is crucial for human T-ALL cell growth in
vivo[56]. We investigated whether there is a stronger association of this locus with T-ALL with
subtype-stratified analysis using a subset of cases in CCRLP with subtype information. The locus
appears to be associated in both T-ALL and B-ALL and we observed a trend of slightly higher
association for T-ALL, but the difference is not statistically significant, likely due to only a small
number of T-ALL cases available (Supplemental Table S8). Although the associated locus
overlaps *TET1*, the most associated SNPs in our meta-analysis were observed as eQTLs of
DNA2, SLC25A16, STOX1 in whole blood or lymphoblastoid cells[57]; the role of these genes in
leukemia has not been explored, and we also cannot verify whether the SNPs may affect *TET1*
expression in hematopoietic stem or progenitor cells. Of the four significant variants in this
locus, SNP rs58627364 lies in the promoter region of *TET1* while the remaining three variants
did not appear to overlap functional elements (Supplementary Figure S5). Further, rs58627364 is

reported to bind to POL2, CCNT2, ETS1, HEY1, and HMGN3 in K562 cells in ENCODE data,
and also significantly alters BCL, BDP1 and NF-kappa B binding motifs. The second locus in
10q21 contains intronic variants in the *TET1* gene, which is well known for its oncogenicity in
several malignancies including AML[55]. A recent study showed the epigenetic regulator *TET1* is
highly expressed in T-cell ALL and is crucial for human T-ALL cell growth in vivo[56]. We
investigated whether there is a stronger association of this locus with T-ALL with subtype
stratified analysis using a small number of cases in CCRLP with subtype information available
(Supplemental Table S8). The locus appears to be associated with both T-ALL and B-ALL and
we observed a trend of slightly higher association for T-ALL, but the difference is not
statistically significant, possibly due to a small number of T-ALL cases.
493
In addition to the discovery of putative novel ALL risk loci, we also capitalized on the large
numbers of Latinos and non-Latino whites included in our study to explore the genetic
architecture of ALL in these two populations, by estimating the heritability explained and the
proportion of population-specific and shared causal alleles. In the NLW population, we estimated
that 20.3% of the heritability of ALL was attributed to common imputed variants using GCTA-
LDMS (Supplementary Table S6A). The estimated heritability increased to 29.8%
(Supplementary Table S6B) if low frequency variants down to MAF of 1% were included,
suggesting that there are additional low frequency variants associated with ALL that may be
discovered in larger scaled studies. However, it is puzzling that the estimated heritability was so
low in LAT (4.1% in univariate analysis, and 7.3% in bivariate analysis; Supplementary Table
S6A, 7). Because the accuracy of imputation at low frequency variants is expected to be
significantly worse in LAT (due to the underrepresentation of Native American or other non-
European haplotypes in HRC panel), a priori we did not estimate the heritability including low-
frequency variants in LAT. However, when we did attempt to estimate heritability in this setting,
we obtain a strongly negative heritability estimates, suggesting blatant model instability or
misspecification, likely attributed to the admixed nature of LAT[58]. This thus brings in question
whether the 4-7% estimates from common variant analysis are robust and accurate. Because the
estimated familial relative risk summed over GWAS loci between NLW and LAT are similar
(Supplementary Table S5), and the estimated effect sizes at known associated loci are highly
correlated (r2 = 0.819; Supplementary Figure S2), we suspect the heritability in Latino
population may be underestimated with the standard REML approach. Our observation suggests
that further efforts to develop a framework to robustly estimate heritability in complex admixed
populations are needed, such as extending model proposed in Zaitlin et al.[59] to 3-way admixed
scenarios.
518
As a consequence of the potential bias in heritability estimates in LAT, our estimated genetic
correlation between LAT and NLW should be interpreted with caution. On the surface, our
estimated genetic correlation (r_G = 0.71) is significantly less than 1, suggesting that there are
significant population-specific components of the disease architecture between LAT and NLW.
This would be consistent with the findings of the *ERG* locus[15,16], a Latino-specific locus
associated with ALL, and suggest that future ethnic-specific GWAS across different ethnic
groups for ALL will be insightful. This is also consistent with our observation in the PESCA
analysis, where we estimated the population-specific and shared causal alleles. We found that
only 32.5% of the estimated causal alleles are shared between LAT and NLW. This contrasts
starkly with the previous investigation of nine complex traits using PESCA between East Asian

and European populations, where most of the causal alleles are shared between populations
across all 9 traits. The result of the PESCA analysis could be partly explained by drastic
difference in power between LAT and NLW currently in our study, and that generally the sample
sizes for ALL are still significantly lower than the complex traits examined in Shi et al.[36]
Another factor could be that because the heritability estimates are used to inform PESCA
analysis, a bias in heritability estimates could impact the estimated number of population-
specific and shared causal alleles. Therefore, the genetic architecture for ALL, particularly in
admixed populations like the Latinos, remain unclear and will require more focused effort to
investigate.
538
Future studies aimed to uncover the genetic risk factors for ALL could focus on multiple
avenues. First, there will be a need to further increase the sample size of the study cohort, which
would provide additional venues to replicate the putative novel findings here and identify more
associated loci. Second, there should be a focus on ethnic-specific GWAS for ALL, as ethnic-
specific associations could be missed in a trans-ethnic GWAS. An example is the *ERG* locus,
which is not genome-wide significant in our meta-analysis. Finally, while not explored
extensively in this particular study, there should be a focus on disentangling the different
subtypes of ALL, and to study other aspects of the disease pathogenesis such as disease
progression or risk of relapse, though these data are less available and may require more focused
ascertainment and cohort creation.
549
550

551 **DESCRIPTION OF SUPPLEMENTAL DATA**
552 Supplemental Data include five figures and eight tables
553

DATA AVAILABILITY
Any uploading of genomic data and/or sharing of these biospecimens or individual data derived
from these biospecimens has been determined to violate the statutory scheme of the California
Health and Safety Code Sections 124980(j), 124991(b), (g), (h), and 103850 (a) and (d), which
protect the confidential nature of biospecimens and individual data derived from biospecimens.
This study was approved by Institutional Review Boards at the California Health and Human
Services Agency, University of Southern California, Yale University, and the University of
California San Francisco. The de-identified newborn dried blood spots for the CCRLP
(California Biobank Program SIS request # 26) were obtained with a waiver of consent from the
Committee for the Protection of Human Subjects of the State of California.
564

ACKNOWLDGEMENT
This work was supported by research grants from the National Institutes of Health
(R01CA155461, R01CA175737, R01ES009137, P42ES004705, P01ES018172, P42ES0470518
and R24ES028524) and the Environmental Protection Agency (RD83451101), United States.
The content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health and the EPA. The collection of cancer
incidence data used in this study was supported by the California Department of Public Health as
part of the statewide cancer reporting program mandated by California Health and Safety Code
Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results
Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of

California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The biospecimens and/or data used in this study were obtained from the California Biobank Program, (SIS request #26), Section 6555(b), 17 CCR. The California Department of Public Health is not responsible for the results or conclusions drawn by the authors of this publication. We thank Hong Quach and Diana Quach for DNA isolation support. We thank Martin Kharrazi, Robin Cooley, and Steve Graham of the California Department of Public Health for advice and logistical support. We thank Eunice Wan, Simon Wong, and Pui Yan Kwok at the UCSF Institute of Human Genetics Core for genotyping support. This study makes use of data generated by the Wellcome Trust Case–Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113 and 085475. Genotype data for COG ALL cases are available for download from dbGaP (Study Accession: phs000638.v1.p1). Data came from a grant, the Resource for Genetic Epidemiology Research in Adult Health and Aging (RC2 AG033067; Schaefer and Risch, PIs) awarded to the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the UCSF Institute for Human Genetics. The RPGEH was supported by grants from the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, Kaiser Permanente Northern California, and the Kaiser Permanente National and Northern California Community Benefit Programs. The RPGEH and the Resource for Genetic Epidemiology Research in Adult Health and Aging are described here: https://divisionofresearch.kaiserpermanente.org/genetics/rpgeh/rpgehhome. For recruitment of subjects enrolled in the CCLS replication set, the authors gratefully acknowledge the clinical investigators at the following collaborating hospitals: University of California Davis Medical Center (Dr. Jonathan Ducore), University of California San Francisco (Drs. Mignon Loh and Katherine Matthay), Children's Hospital of Central California (Dr. Vonda Crouse), Lucile Packard Children's Hospital (Dr. Gary Dahl), Children's Hospital Oakland (Dr. James Feusner), Kaiser Permanente Roseville (formerly Sacramento) (Drs. Kent Jolly and Vincent Kiley), Kaiser Permanente Santa Clara (Drs. Carolyn Russo, Alan Wong, and Denah Taggart), Kaiser Permanente San Francisco (Dr. Kenneth Leung), and Kaiser Permanente Oakland (Drs. Daniel Kronish and Stacy Month). The authors additionally thank the families for their participation in the California Childhood Leukemia Study (formerly known as the Northern California Childhood Leukemia Study). Finally, the authors acknowledge the Center for Advanced Research Computing (CARC; https://carc.usc.edu) at the University of Southern California for providing computing resources that have contributed to the research results reported within this publication.

DECLARATION OF INTEREST
The authors declare no competing interests.

616 **Table 1**. Summary statistics for the reported variants, the top variant in the loci from our meta-
617 analysis, and the linkage disequilibrium between the two variants in NLW and LAT.

	Reported SNP				Top SNP in this study				r^2	
Gene	Chr	Pos	rsID (reference)	P-value	Chr	Pos	rsID	P-value	NLW	LAT
C5orf56	5	131765206	rs886285 (ref [18])	0.63	5	131811182	rs11741255	1.69×10^{-4}	0.35	0.19
BAK1	6	3354693	rs1048728818 (ref [18])	4.49×10^{-8}	6	33546837	rs210142	4.27×10^{-8}	1	1
IKZF1	7	50470604	rs4132601 (ref [5])	1.13×10^{-33}	7	50477144	rs10230978	3.92×10^{-34}	0.98	0.97
8q24	8	130156143	rs4617118 (ref [4])	1.04×10^{-12}			Same			
CDKN2A	9	21970916	rs3731249 (ref [27])	1.29×10^{-18}	9	21975319	rs36228834	1.90×10^{-18}	0.99	1
TLE1	9	83747371	rs76925697 (ref [18])	5.37×10^{-2}	9	83728588	rs62579826	1.06×10^{-2}	0.81	0.98
GATA3	10	8104208	rs3824662 (ref [6])	4.24×10^{-9}			Same			
PIP4K2A	10	22852948	rs7088318 (ref [8])	6.50×10^{-19}	10	22853102	rs7075634	2.42×10^{-19}	0.96	0.97
BMI1	10	22423302	rs11591377 (ref [28])	8.21×10^{-10}	10	22374489	rs1926697	5.24×10^{-10}	0.84	0.88
ARID5B	10	63723577	rs10821936 (ref [7])	4.78×10^{-67}	10	63721176	rs7090445	7.36×10^{-70}	0.98	0.99
LHPP	10	126293309	rs35837782 (ref [3])	6.90×10^{-4}			Same			
ELK3	12	96612762	rs4762284 (ref [3])	2.42×10^{-3}	12	96645605	rs78405390	4.68×10^{-5}	0.13	0.22
CEBPE	14	23589057	rs2239633 (ref [5])	3.0×10^{-14}	14	23589349	rs2239630	2.12×10^{-21}	0.74	0.78
IKZF3	17	38066240	rs2290400 (ref [4])	$2.09 \ 10^{-6}$	17	37957235	rs17607816	1.42×10^{-7}	0.02	0.22
IGF2BP1	17	47092076	rs10853104 (ref [18])	2.93×10^{-2}	17	47217004	rs6504598	4.87×10^{-4}	0.02	0.02
ERG	21	39789606	rs8131436 (ref [16])	6.97×10^{-5}	21	39784752	rs55681902	9.36×10^{-6}	0.62	0.65

Definition of terms: Reported SNP; variant associated with ALL in previous papers. Out top
SNP: variant with lowest P-value at 1Mb around the reported SNP in the transethnic meta-
analysis; Gene: nearest gene unless the variant is in gene desert. Chr., chromosome; Pos.,
Position in hg19; P-value, logistic regression test value, r2: squared correlation of the reported
SNP and our top SNP; NLW: non-Latino white cohort; LAT: Latino cohort

Table 2. Summary of conditional analysis to identify secondary associations at known loci.
624

Gene	Chr	Pos	rsID	Risk allele	OR	$P_{conditional}$	$P_{discovery}$	r2
IKZF1	7	50459043	rs78396808	A	1.632	3.46×10^{-26}	2.7×10^{-16}	*0.06
CDKN2A/B	9	21993964	rs2811711	T	1.355	7.2×10^{-10}	1.85×10^{-11}	0.01
CEBPE	14	23592617	rs60820638	A	1.193	5.38×10^{-8}	0.102	0.16
IZKF3	17	37983492	rs12944882	T	1.204	7.71×10^{-10}	2.81×10^{-7}	0.02

For each of the four significant association after conditional analysis, we show the genomic
coordinates in hg19, effect size (OR), the P-values with or without conditioning on the lead SNP
from the discovery meta-analysis in the locus, and the r2 between the lead SNP and secondary
association.

Chr., chromosome; Pos;. Position in hg19; OR: Effect size; $P_{conditional}$: p-value from the
conditional analysis; $P_{discovery}$: p –value from meta-analysis without conditioning on any SNP; r2:
squared correlation of the conditioned SNP and the most significantly associated SNP from
conditional analysis.

*calculated in Latino population as the variant was filtered out for low MAF in NLW cohort.

REFERENCES

1. Giddings, B. M., Whitehead, T. P., Metayer, C. & Miller, M. D. Childhood leukemia incidence in
California: High and rising in the Hispanic population: Hispanic Childhood Leukemia Incidence.
Cancer **122**, 2867–2875 (2016).

2. Lim, J. Y.-S., Bhatia, S., Robison, L. L. & Yang, J. J. Genomics of racial and ethnic disparities in
childhood acute lymphoblastic leukemia. *Cancer* **120**, 955–962 (2014).

3. Vijayakrishnan, J. *et al.* A genome-wide association study identifies risk loci for childhood acute
lymphoblastic leukemia at 10q26.13 and 12q23.1. *Leukemia* **31**, 573–579 (2017).

4. Wiemels, J. L. *et al.* GWAS in childhood acute lymphoblastic leukemia reveals novel genetic
associations at chromosomes 17q12 and 8q24.21. *Nat. Commun.* **9**, 286 (2018).

5. Papaemmanuil, E. *et al.* Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of
childhood acute lymphoblastic leukemia. *Nat. Genet.* **41**, 1006–1010 (2009).

6. Perez-Andreu, V. *et al.* Inherited GATA3 variants are associated with Ph-like childhood acute
lymphoblastic leukemia and risk of relapse. *Nat. Genet.* **45**, 1494–1498 (2013).

7. Treviño, L. R. *et al.* Germline genomic variants associated with childhood acute lymphoblastic
leukemia. *Nat. Genet.* **41**, 1001–1005 (2009).

8. Xu, H. *et al.* Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic
leukemia in ethnically diverse populations. *J. Natl. Cancer Inst.* **105**, 733–742 (2013).

9. Feng, Q. *et al.* Trends in Acute Lymphoblastic Leukemia Incidence in the United States by
Race/Ethnicity From 2000 to 2016. *Am. J. Epidemiol.* kwaa215 (2020)
doi:10.1093/aje/kwaa215.

10.   Linabery, A. M. & Ross, J. A. Trends in childhood cancer incidence in the U.S. (1992-
2004). *Cancer* **112**, 416–432 (2008).

11.   Barrington-Trimis, J. L. *et al.* Trends in childhood leukemia incidence over two decades
from 1992 to 2013. *Int. J. Cancer* **140**, 1000–1008 (2017).

12.   Bhatia, S. *et al.* Racial and ethnic differences in survival of children with acute
lymphoblastic leukemia. *Blood* **100**, 1957–1964 (2002).

13.   Kadan-Lottick, N. S. Survival Variability by Race and Ethnicity in Childhood Acute
Lymphoblastic Leukemia. *JAMA* **290**, 2008 (2003).

14.   Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164
(2016).

15.   Qian, M. *et al.* Novel susceptibility variants at the ERG locus for childhood acute
lymphoblastic leukemia in Hispanics. *Blood* **133**, 724–729 (2019).

16.   de Smith, A. J. *et al.* Heritable variation at the chromosome 21 gene ERG is associated
with acute lymphoblastic leukemia risk in children with and without Down syndrome. *Leukemia*
33, 2746–2751 (2019).

17.   Walsh, K. M. *et al.* A Heritable Missense Polymorphism in *CDKN2A* Confers Strong Risk
of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal
Evolution. *Cancer Res.* **75**, 4884–4894 (2015).

18.   Vijayakrishnan, J. *et al.* Identification of four novel associations for B-cell acute
lymphoblastic leukaemia risk. *Nat. Commun.* **10**, 5348 (2019).

19.   Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
disparities. *Nat. Genet.* **51**, 584–591 (2019).

20.   Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
complex traits. *Nature* **570**, 514–518 (2019).

21.   Mahajan, A. *et al. Trans-ancestry genetic study of type 2 diabetes highlights the power
of diverse populations for discovery and translation*.
http://medrxiv.org/lookup/doi/10.1101/2020.09.22.20198937 (2020)
doi:10.1101/2020.09.22.20198937.

22.   The 1000 Genomes Project Consortium. A global reference for human genetic variation.
Nature **526**, 68–74 (2015).

23.   the Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for
genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).

24.   Genome Aggregation Database Consortium *et al.* The mutational constraint spectrum
quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).

25.   Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

26.   Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method
for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**, 906–913
(2007).

27.   Vijayakrishnan, J. *et al.* The 9p21.3 risk of childhood acute lymphoblastic leukaemia is
explained by a rare high-impact variant in CDKN2A. *Sci. Rep.* **5**, 15065 (2015).

28.   de Smith, A. J. *et al.* BMI1enhancer polymorphism underlies chromosome 10p12.31
association with childhood acute lymphoblastic leukemia: *BMI* 1 enhancer polymorphism in ALL.
Int. J. Cancer **143**, 2647–2658 (2018).

29.   Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000
cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661–678 (2007).

30.   Metayer, C. *et al.* Tobacco smoke exposure and the risk of childhood acute
lymphoblastic and myeloid leukemias by cytogenetic subtype. *Cancer Epidemiol. Biomark. Prev.
Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol.* **22**, 1600–1611 (2013).

31.   Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
datasets. *GigaScience* **4**, 7 (2015).

32.   Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare
ROC curves. *BMC Bioinformatics* **12**, 77 (2011).

33.   Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
Complex Trait Analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).

34.   The LifeLines Cohort Study *et al.* Genetic variance estimation with imputed variants finds
negligible missing heritability for human height and body mass index. *Nat. Genet.* **47**, 1114–
1120 (2015).

35.   the PRACTICAL consortium *et al.* The contribution of rare variation to prostate cancer
heritability. *Nat. Genet.* **48**, 30–35 (2016).

36.   Shi, H. *et al.* Localizing Components of Shared Transethnic Genetic Architecture of
Complex Traits from GWAS Summary Data. *Am. J. Hum. Genet.* **106**, 805–817 (2020).

37.   Berisa, T. & Pickrell, J. K. Approximately independent linkage disequilibrium blocks in
human populations. *Bioinformatics* btv546 (2015) doi:10.1093/bioinformatics/btv546.

38.   Schumacher, F. R. *et al.* Association analyses of more than 140,000 men identify 63
new prostate cancer susceptibility loci. *Nat. Genet.* **50**, 928–936 (2018).

39.   Wiemels, J. L. *et al.* A functional polymorphism in the CEBPE gene promoter influences
acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor
Ikaros. *Leukemia* **30**, 1194–1197 (2016).

40.   Studd, J. B. *et al.* Genetic predisposition to B-cell acute lymphoblastic leukemia at
14q11.2 is mediated by a CEBPE promoter polymorphism. *Leukemia* **33**, 1–14 (2019).

41.   Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states,
conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic
Acids Res.* **40**, D930-934 (2012).

42.   Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**,
580–585 (2013).

43.   Lin, B. D. *et al.* 2SNP heritability and effects of genetic variants for neutrophil-to-
lymphocyte and platelet-to-lymphocyte ratio. *J. Hum. Genet.* **62**, 979–988 (2017).

44.   Stadhouders, R. *et al.* HBS1L-MYB intergenic variants modulate fetal hemoglobin via
long-range MYB enhancers. *J. Clin. Invest.* **124**, 1699–1710 (2014).

45.   Guo, M. H. *et al.* Comprehensive population-based genome sequencing provides insight
into hematopoietic regulatory mechanisms. *Proc. Natl. Acad. Sci.* **114**, E327–E336 (2017).

46.   Astle, W. J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to
Common Complex Disease. *Cell* **167**, 1415-1429.e19 (2016).

47.   van Rooij, F. J. A. *et al.* Genome-wide Trans-ethnic Meta-analysis Identifies Seven
Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis. *Am. J.
Hum. Genet.* **100**, 51–63 (2017).

48.   Tajuddin, S. M. *et al.* Large-Scale Exome-wide Association Analysis Identifies Loci for
White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. *Am. J. Hum. Genet.*
99, 22–39 (2016).

49.   Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–D1012
(2019).

50.   Ahola-Olli, A. V. *et al.* Genome-wide Association Study Identifies 27 Loci Influencing
Concentrations of Circulating Cytokines and Growth Factors. *Am. J. Hum. Genet.* **100**, 40–50
(2017).

51.   Chang, J. S. *et al.* Profound deficit of IL10 at birth in children who develop childhood
acute lymphoblastic leukemia. *Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res.*
Cosponsored Am. Soc. Prev. Oncol. **20**, 1736–1740 (2011).

52.   Lynch, J. R. *et al.* JMJD1C-mediated metabolic dysregulation contributes to HOXA9-
dependent leukemogenesis. *Leukemia* **33**, 1400–1410 (2019).

53.   Chen, M. *et al.* JMJD1C is required for the survival of acute myeloid leukemia by
functioning as a coactivator for key transcription factors. *Genes Dev.* **29**, 2123–2139 (2015).

54.   Xiao, F. *et al.* JMJD1C Ensures Mouse Embryonic Stem Cell Self-Renewal and Somatic
Cell Reprogramming through Controlling MicroRNA Expression. *Stem Cell Rep.* **9**, 927–942
(2017).

55.   Cimmino, L. *et al.* TET1 is a tumor suppressor of hematopoietic malignancy. *Nat.*
Immunol. **16**, 653–662 (2015).

56.   Bamezai, S. *et al.* TET1 promotes growth of T-cell acute lymphoblastic leukemia and
can be antagonized via PARP inhibition. *Leukemia* (2020) doi:10.1038/s41375-020-0864-3.

57.   Lappalainen, T. *et al.* Transcriptome and genome sequencing uncovers functional
variation in humans. *Nature* **501**, 506–511 (2013).

58.   Steinsaltz, D., Dahl, A. & Wachter, K. W. On Negative Heritability and Negative
Estimates of Heritability. *Genetics* **215**, 343–357 (2020).

59.   Zaitlen, N. *et al.* Leveraging population admixture to characterize the heritability of
complex traits. *Nat. Genet.* **46**, 1356–1362 (2014).

Figure1. Summary result of the trans-ethnic meta-analysis on ALL.
Results of the meta-analysis is represented by the Manhattan plot. The novel loci from this study are marked with dotted lines and labeled with the nearest genes. Significance threshold at genome-wide significance level ($5x10^{-8}$) is marked with a horizontal dashed grey line in the Manhattan plot. The y-axis is truncated at $-log10(1x10^{-50})$ to improve readability. The insert shows the Quantile-Quantile plot. Deviation from the expected p-value distribution is evident only in the tail. There is little evidence of inflation of the test statistics in general as the genomic inflation factor is 1.024.

Figure2. Novel loci associated with childhood ALL in trans-ethnic meta-analysis.
LocusZoom plots showing 1 Mb region around the identified loci near (A) MYB/HBS1L on
chr6, (B) NRBF2/JMJD1C on chr10, and (C) TET1 on chr10 are shown. Diamond symbol
indicates the lead SNP in each locus. Color of remaining SNPs is based on linkage
disequilibrium (LD) as measured by r2 with the lead SNP in non-Latino white. All coordinates
in x-axis are in hg19.

Figure 3. Secondary association signal (p < 5x10^{-8}) with ALL found in previously known loci through conditional analysis. LocusZoom plot displaying the 1 Mb region found to harbor a second novel variant associated with ALL through conditional analysis: (A) IKZF1 (B) CDKN2A (C) CEBPE (D) IKZF3. For each locus, we display the pattern of association before(left) and after(right) conditioning on the top associated variant in the locus. In both cases, diamond indicates the lead SNP in the conditional analysis. Color of the remaining SNPs is based on linkage disequilibrium (LD) with the lead variant in the conditional analysis in non-Latino white. Genomic coordinates on x-axis are in hg19.